Takeda Pharmaceutical Company Ltd (TAK)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO

Board of Directors appoints Julie Kim as Representative Director, President & CEO following shareholder vote Announces new appointments and...

Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3...

Form IRANNOTICE - Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (Exchange Act Section 13(r)).

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1

- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad...

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque...

U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease

If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]